Diplomat Pharmacy (DPLO) Misses Q4 EPS by 9c

Diplomat Pharmacy (NYSE: DPLO) reported Q4 EPS of $0.08, $0.09 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $1.15 billion versus the consensus estimate of $1.18 billion.

Fourth Quarter 2016 Highlights include:

• Revenue of $1,145 million, an increase of 16% or $158 million
  • 4% organic revenue growth
• Total prescriptions dispensed of 242,000, an increase of 2%
• Gross margin of 7.3% versus 7.8%
  • Gross profit per prescription dispensed of $342, compared to $312
• Net (loss) income attributable to Diplomat of $(1.1) million, compared to $3.6 million
• Adjusted EBITDA of $26.1 million, compared to $28.1 million
  • Adjusted EBITDA margin of 2.3% versus 2.8%
• EPS of $(0.02) per diluted common share versus $0.05
  • Adjusted EPS of $0.08 versus $0.21

2017 Financial Outlook

For the full-year 2017, we provide financial guidance as follows:

• Revenue between $4.3 and $4.7 billion
• Net income attributable to Diplomat between $6.5 and $15.5 million
• Adjusted EBITDA between $95 and $103 million
• Diluted EPS between $0.09 and $0.23
• Adjusted EPS between $0.54 and $0.70

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Movano (MOVE) Misses Q2 EPS by 195c